Overview
Pharmaceutical

Noile-Immune Biotech Inc.

Noile-Immune Biotech is a clinical-stage biopharmaceutical company focused on the development of next-generation CAR-T cell therapies for solid tumors, leveraging its proprietary PRIME technology exclusively licensed from Yamaguchi University. PRIME technology activates not only the administered CAR-T cells but also the patient's endogenous immune cells, offering a differentiated mechanism of action against solid cancers where conventional CAR-T therapies have limited efficacy. The company operates a hybrid business model combining in-house drug discovery pipelines with PRIME technology licensing partnerships to accelerate commercialization and diversify revenue.

Market Cap
¥3.82B
US$24.4M
EV
¥0.27B
US$1.75M
Stock¥88▼-1.12%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
—
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
1.1
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-67.0%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
3.82BUS$24.4MMarket Cap0.00BUS$0.00M+ Debt3.54BUS$22.6M− Cash0.00BUS$0.00M− Inv. Sec.0.27BUS$1.75MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.32US$2.02M'23/120.01US$0.04M'24/120.01US$0.03M'25/12
Net Income 5Y (¥B)
-1.13-US$7.21M'23/12-0.96-US$6.15M'24/12-0.79-US$5.06M'25/12
Capital Structure
100%
EquityD/E 0.00xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
5.56US$35.4M'23/124.67US$29.8M'24/123.92US$25.0M'25/12
Shareholders
Top 10 hold 67.0%
1
Takeda Pharmaceutical Company Limited
18.70%
2
Tsurukame Co., Ltd.
16.49%
3
Koji TAMADA
8.71%
4
KOREA SECURITIES DEPOSITORY-SAMSUNG (Standing Proxy: Citibank, N.A., Tokyo Branch)
8.47%
5
Kyoko SETO
3.22%
6
Daiwa Nichidai Bio Venture Investment Limited Partnership
3.10%
7
Hiroko OGIHARA
2.30%
8
Yukimi SAKODA
2.30%
9
Satoshi WADA
2.20%
10
Apricot Co., Ltd.
1.56%
Management
8 officers
Koji TAMADA
Representative Director, President
Mar 1992: Graduated from Faculty of Medicine, Kyushu University May 1992: Obtained medical license Jun 1992: Joined Department of Urology, Faculty of Medicine, Kyushu University Apr 1998: Postdoctoral Fellow, Mayo Clinic College of Medicine, USA Oct 2002: Assistant Professor, Mayo Clinic College of Medicine Aug 2005: Assistant Professor, Johns Hopkins University School of Medicine, USA Sep 2009: Associate Professor, University of Maryland School of Medicine, USA May 2011: Professor, Department of Immunology, Graduate School of Medicine, Yamaguchi University (current) Mar 2016: Director, the Company Sep 2020: Representative Director, President, the Company (current)
1968-03-28
Tsutomu TOKASHIKI
Director, General Manager, Business Planning and Research Division
Jun 2006: Joined OncoTherapy Science, Inc. Dec 2014: Representative Director, Leading Valley Inc. Jul 2015: Joined the Company Jan 2018: General Manager, Business Planning Department, Management Administration Division, the Company May 2019: Director, the Company Jun 2019: Head of Business Division and General Manager, Business Planning Department, the Company Jan 2020: General Manager, Business Planning and Research Division, the Company (current)
1981-12-14
Hiroko NAGAI
Director, General Manager, Administration Division
Apr 1999: Joined Nagano & Morita CPA Jun 2003: Licensed as Certified Public Accountant (Illinois, USA) Feb 2004: Joined Ernst & Young, Global Financial Services Oct 2010: Established Hiroko Nagai CPA Office, Representative Mar 2020: Joined the Company; General Manager, Administration Division (current) Jun 2020: Director, the Company (current)
1976-10-05
Philippe FAUCHET
Director
Jun 2001: President, Sanofi Mama K.K. (now Sanofi K.K.) May 2005: Representative Director, President, Sanofi-Aventis K.K. (now Sanofi K.K.) Jan 2010: President, GlaxoSmithKline K.K. Apr 2017: Chairman, GlaxoSmithKline K.K. May 2019: Outside Director, Bonac Corporation Mar 2020: Outside Director, the Company (current) Sep 2020: Outside Director, Rezolute Inc. (current) Jun 2022: Outside Director, Luca Science Inc. (current) Jun 2022: Outside Director, JCR Pharmaceuticals Co., Ltd. (current) Jun 2023: Director, General Incorporated Association Medical Excellence JAPAN (MEJ) (current)
1957-11-02
Nobuo HANAI
Director
Apr 1976: Joined Kyowa Hakko Kogyo Co., Ltd. Feb 2003: Established BioWa, Inc., and assumed position of President Mar 2012: Representative Director, President, Kyowa Hakko Kirin Co., Ltd. Mar 2018: Representative Director, Chairman, Kyowa Hakko Kirin Co., Ltd. May 2020: Director, LIVES Capital Inc. Jun 2020: Outside Director, Shimadzu Corporation (current) Mar 2021: Outside Director, Perseus Proteomics Inc. (current) Mar 2024: Outside Director, the Company (current) Jun 2025: Director, LIVES Inc. (current)
1953-04-30
Kazuyuki FUJIWARA
Full-time Audit and Supervisory Board Member
Apr 1981: Joined Shinnihon Securities Co., Ltd. (now Mizuho Securities Co., Ltd.) Apr 2011: Executive Officer and Third Block General Manager, Mizuho Securities Co., Ltd. Apr 2012: Deputy General Manager, Marketing Division, Shinko Investment Trust Co., Ltd. Oct 2016: Full-time Audit and Supervisory Board Member, Mizuho Securities Property Management Co., Ltd. Jun 2018: Adviser, Mizuho Securities Property Management Co., Ltd. Jul 2019: Full-time Outside Audit and Supervisory Board Member, the Company (current)
1958-08-14
Hiroshige HASHIOKA
Audit and Supervisory Board Member
Apr 1991: Joined Sumitomo Bank, Ltd. (now Sumitomo Mitsui Banking Corporation) Apr 1998: Registered as attorney-at-law Sep 2004: Outside Director, Golf Digest Online Inc. Jun 2007: Outside Audit and Supervisory Board Member, United Arrows Ltd. Aug 2008: Established Vasco da Gama Law & Accounting Office; Founding Partner Attorney (current) Jun 2011: Outside Audit and Supervisory Board Member, A.P. Company Co., Ltd. Jun 2011: Outside Audit and Supervisory Board Member, Trenders Inc. (current) Jun 2014: Outside Audit and Supervisory Board Member, iFreak Mobile Inc. Jul 2015: Outside Audit and Supervisory Board Member, the Company (current) Jan 2017: Outside Audit and Supervisory Board Member, Locoguide Inc. Jun 2018: Outside Director, Locoguide Inc. Oct 2021: Outside Director, Kufu Company Holdings Inc. (formerly Kufu Co., Ltd.) (current)
1967-01-23
Yukiyasu NAKADA
Audit and Supervisory Board Member
Oct 1996: Joined Asahi Audit Corporation (now Azusa Audit LLC) Apr 1999: Registered as Certified Public Accountant Oct 2001: Joined PwC Tax Corporation Aug 2009: Registered as Certified Public Tax Accountant Sep 2017: Established Yukiyasu Nakada Accounting & Tax Office, Representative (current) Apr 2018: Director, Melk Inc. (now Cocolport Inc.) May 2019: Outside Audit and Supervisory Board Member, the Company (current) May 2022: Outside Audit and Supervisory Board Member, Promat Japan Co., Ltd. Dec 2023: Outside Audit and Supervisory Board Member, Authlete Inc. (current)
1974-03-15
Large Shareholding Reports
Okasan Securities Co., Ltd.
2026-10-22
18.26%→17.51%
Okasan Securities Co., Ltd.
2026-10-16
19.29%→18.26%
Okasan Securities Co., Ltd.
2026-10-09
19.29%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-10-22
Large Shareholding Report
EDINET
2026-10-16
Large Shareholding Report
EDINET
2026-10-09
Large Shareholding Report
EDINET
2026-09-18
Securities Registration Statement
TDnet
2026-08-13
Q2 Earnings Flash
FY ending Dec 2026
EDINET
2026-08-13
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-05-14
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-03-23
Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-11-13
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-08-08
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-05-12
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-28
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINETAmended
2024-10-15
Amended Semi-Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-08-13
Semi-Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-05-14
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-29
Annual Securities Report
Period: Jan 2023 – Dec 2023
EDINET
2023-11-13
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-14
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →